-

SEQUENCE LISTING

<110> AB Science <120> Use of tyrosine kinase inhibitors for treating cerebral ischemia <130> D21220 NT <150> US 60/465,789 <151> 2003-04-28 <160> 5 <170> PatentIn Ver. 2.1 <210> 1 <211> 976 <212> PRT <213> Homo sapiens <220> <223> Human c-kit Met Arg Gly Ala Arg Gly Ala Trp Asp Phe Leu Cys Val Leu Leu 15 Leu Leu Arg Val Gln Thr Gly Ser Ser Gln Pro Ser Val Ser Pro Gly 25 30 Glu Pro Ser Pro Pro Ser Ile His Pro Gly Lys Ser Asp Leu Ile Val Arg Val Gly Asp Glu Ile Arg Leu Leu Cys Thr Asp Pro Gly Phe Val 50Lys Trp Thr Phe Glu Ile Leu Asp Glu Thr Asn Glu Asn Lys Gln Asn Glu Trp Ile Thr Glu Lys Ala Glu Ala Thr Asn Thr Gly Lys Tyr Thr $85 \hspace{1cm} 90 \hspace{1cm} 95$ Cys Thr Asn Lys His Gly Leu Ser Asn Ser Ile Tyr Val Phe Val Arg Asp Pro Ala Lys Leu Phe Leu Val Asp Arg Ser Leu Tyr Gly Lys Glu 115 120 125 Asp Asn Asp Thr Leu Val Arg Cys Pro Leu Thr Asp Pro Glu Val Thr Asn Tyr Ser Leu Lys Gly Cys Gln Gly Lys Pro Leu Pro Lys Asp Leu Arg Phe Ile Pro Asp Pro Lys Ala Gly Ile Met Ile Lys Ser Val Lys Arg Ala Tyr His Arg Leu Cys Leu His Cys Ser Val Asp Gln Glu Gly

Lys Ser Val Leu Ser Glu Lys Phe Ile Leu Lys Val Arg Pro Ala Phe 195 200 205

Lys Ala Val Pro Val Val Ser Val Ser Lys Ala Ser Tyr Leu Leu Arg

WO 2004/096225 PCT/IB2004/001874

		2								214									
Glu 225	Gly	G.	lu	Glu	Phe	Thr 230	Val	Th	r (:ys	Thr	11∈ 235	Ly	s A	sp 7	Jal	Ser	Se 24	r 0
Ser	Val	T	yr	Ser	Thr 245	Trp	Lys	Ar	g (Glu	Asn 250	Ser	: G1	n T	hr :	Lys	Leu 255	Gl	n
Glu	Lys	т	yr	Asn 260	Ser	Trp	His	Hi.	s (31 <u>y</u> 265	Asp	Ph€	e As	sn T	'yr	Glu 270	Arg	G1	.n
Ala	Thi		eu 75	Thr	Ile	Ser	Sei	Al 28	a 2	Arg	Val	Ası	n As	sp S	Ser 285	Gly	Val	Pħ	ıe
Met	Cy:		'yr	Ala	Asn	Asr	Th: 29!	e Př	ne	Gly	Ser	Al	a A 3	sn ' 00	Val	Thr	Thr	Tì	nr
Leu 305		u V	/al	Val	Asp	Lys 310	Gl;	y Pì	ne	Ile	Asr	11 31	e P 5	he	Pro	Met	Ile	: A:	sn 20
Thr	Th	r \	/al	Phe	Val 325	. Ası	n As	p G	lу	Glu	Asr 330	ı Va	l A	.sp	Leu	Ile	Val 339	. G	lu
Tyr	Gl	u I	Ala	Phe	Pro	Ly:	s Pr	o G	lu	His 345	Gl	n Gl	n T	rp	Ile	Туг 350	Met	: A	sn
Arg	Th		Phe 355	Thr	Ası	b FA	s Tr	р G 3	lu 60	Asp	Ty:	r Pi	:0 I	ys	Ser 365	Glu	Ası	n G	lu
Sei	: As		Ile	Arç	ту	r Va	1 Se	r G	lu	Leu	Hi	s Le	eu T	Thr 380	Arg	Le	ı Ly	s G	31y
Th:		Lu	Gl,	/ Gly	/ Th	r Ty 39	r Ti	r F	he	Leu	ı Va	1 S	er 1 95	Asn	Ser	Ası	o Va	1 F	neA 100
Al	a Ai	La	Ile	e Ala	a Ph 40	e As 5	n Vá	al T	yr	Val	As 41	n T	hr :	Lys	Pro	Gl:	u Il 41	e I 5	Leu
Th	r T	yr	Ası	Ar 42	g Le O	u Va	1 A:	sn (31 y	Met 425	Le 5	u G	ln	Cys	Val	A1 43	a Al O	a (Gly
Ph	e P	ro	G1:	u Pr 5	o Tr	r I	le A	sp '	Trp 440	ту:	r Ph	ne C	уs	Pro	Gl 5 4 4 5	7 Th	r Gl	u (Gln
Ar		ys 50	Se	r Al	a Se	er Va	al L 4	eu 55	Pro	Va	1 As	sp V	al	Gln 460	Thi	r Le	u As	sn	Ser
S e		ly	Pr	o Pr	o Pi	ne G	ly L 70	ys	Leı	Va د	1 V	al (31n 175	Ser	Se	r Il	e As	яp	Ser 480
Se	er A	la	Ph	e Ly	s H	is A 85	sn G	ly	Thi	r Va	1 G 4	lu (90	Cys	Lys	Al.	а Ту	/r A	sn 95	Asp
Vá	al C	31 y	LУ	's Th 50	nr S	er A	la 1	`yr	Ph	e As	n P	he i	Ala	Phe	e Ly	s G:	Ly A 10	sn	Asn
L	ys (31 u	G) 51	in I:	le H	is P	ro l	lis	Th 52	r Le	eu P	he	Thr	Pro	5 Le	u Lo 5	eu I	le	Gly
P	he '	/al	. 13	le V	al A	la G	ly t	Met 535	Me	t Cy	ys I	le	Ile	Va. 54	1 Me 0	t I	le L	eu	Thr
	yr 45	Lys	5 Т	yr L	eu G	in I	.ys 550	Pro	Me	t T	yr 🤆	Slu	Val 555	G1:	n Tı	p L	ys V	'al	Val 560
G	lu	Glı	Ι	le A	sn (Sly 2 565	Asn	Asn	ту	r V	al ?	fyr 570	Ile	As	p Pı	co T	hr (1n 75	Leu

3/4

		3/4													
Pro	Tyr	Asp	His 580	Lys	Trp	Glu	Phe	Pro 585	Arg	Asn	Arg	Leu	Ser 590	Phe	Gly
Lys	Thr	Leu 595	Gly	Ala	Gly	Ala	Phe 600	Gly	Lys	Val	Val	Glu 605	Ala	Thr	Ala
Tyr	Gly 610	Leu	Ile	Lys	Ser	Asp 615	Ala	Ala	Met	Thr	Val 620	Ala	Val	Lys	Met
Leu 625	Lys	Pro	Ser	Ala	His 630	Leu	Thr	Glu	Arg	Glu 635	Ala	Leu	Met	Ser	Glu 640
Leu	Lys	Val	Leu	Ser 645	Tyr	Leu	Gly	Asn	His 650	Met	Asn	Ile	Val	Asn 655	Leu
Leu	Gly	Ala	Cys 660	Thr	Ile	Gly	Gly	Pro 665	Thr	Leu	Val	Ile	Thr 670	Glu	Tyr
Cys	Суѕ	Tyr 675	Gly	Asp	Leu	Leu	Asn 680	Phe	Leu	Arg	Arg	Lys 685	Arg	Asp	Ser
Phe	Ile 690	Суѕ	Ser	Lys	Gln	Glu 695	Asp	His	Ala	Glu	Ala 700	Ala	Leu	Tyr	Lys
Asn 705	Leu	Leu	His	Ser	Lys 710	Glu	Ser	Ser	Суѕ	Ser 715	Asp	Ser	Thr	Asn	Glu 720
Tyr	Met	Asp	Met	Lys 725	Pro	Gly	Val	Ser	Tyr 730	Val	Val	Pro	Thr	Lys 735	Ala
Asp	Lys	Arg	Arg 740	Ser	Val	Arg	Ile	Gly 745	Ser	Tyr	Ile	Glu	Arg 750	Asp	Val
Thr	Pro	Ala 755	Ile	Met	Glu	Asp	Asp 760	Glu	Leu	Ala	Leu	Asp 765	Leu	Glu	Asp
Leu	Leu 770	Ser	Phe	Ser	Ţyr	Gln 775	Val	Ala	Lys	Gly	Met 780	Ala	Phe	Leu	Ala
Ser 785	Lys	Asn	Cys	Ile	His 790	Arg	Asp	Leu	Ala	Ala 795	Arg	Asn	Ile	Leu	Leu 800
Thr	His	Gly	Arg	Ile 805	Thr	Lys	Ile	Cys	Asp 810	Phe	Gly	Leu	Ala	Arg 815	Asp
Ile	Lys	Asn	Asp 820	Ser	Asn	Tyr	Val	Val 825	Lys	Gly	Asn	Ala	Arg 830	Leu	Pro
Val	Lys	Trp 835	Met	Ala	Pro	Glu	Ser 840	Ile	Phe	Asn	Cys	Val 845	Tyr	Thr	Phe
Glu	Ser 850	Asp	Val	Trp	Ser	Tyr 855	Gly	Ile	Phe	Leu	Trp 860	Glu	Leu	Phe	Ser
Leu 865	-	Ser	Ser	Pro	Tyr 870	Pro	Gly	Met	Pro	Val 875	Asp	Ser	Lys	Phe	Tyr 880
Lys	Met	Ile	Lys	Glu 885	Gly	Phe	Arg	Met	Leu 890	Ser	Pro	Glu	His	Ala 895	Pro
Ala	Glu	Met	Tyr 900	Asp	Ile	Met	Lys	Thr 905	Cys	Trp	Asp	Ala	Asp 910	Pro	Leu
Lys	Arg	Pro 915		Phe	Lys	Gln	Ile 920	Val	Gln	Leu	Ile	Glu 925		Gln	Ile

<220> <223> Primer <400> 5

gtcagacaaa atgatgcaac

4/4 Ser Glu Ser Thr Asn His Ile Tyr Ser Asn Leu Ala Asn Cys Ser Pro 935 930 Asn Arg Gln Lys Pro Val Val Asp His Ser Val Arg Ile Asn Ser Val Gly Ser Thr Ala Ser Ser Ser Gln Pro Leu Leu Val His Asp Asp Val 965 <210> 2 <211> 30 <212> DNA <213> Homo sapiens <220> <223> Primer <400> 2 30 aagaagagat ggtacctcga ggggtgaccc <210> 3 <211> 33 <212> DNA <213> Homo sapiens <220> <223> Primer <400> 3 33 ctgcttcgcg gccgcgttaa ctcttctcaa cca <210> 4 <211> 20 <212> DNA <213> Homo sapiens <220> <223> Primer <400> 4 20 agctcgttta gtgaaccgtc <210> 5 <211> 20 <212> DNA <213> Homo sapiens

20